15-gene expression profile and PRAME as an integrated prognostic test for uveal melanoma: First report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)

Validated and accurate prognostic testing is critical for precision medicine in uveal melanoma (UM). Our aims were to (1) prospectively validate an integrated prognostic classifier combining a 15-gene expression profile (15-GEP) and PRAME RNA expression, and (2) identify clinical variables that enhance the prognostic accuracy of the 15-GEP/PRAME classifier., This study included 1577 subjects with UM enrolled in the Collaborative Ocular Oncology Group Study Number 2 (COOG2) and prospectively monitored across 26 centers. All subjects underwent testing of their primary UM sample with DecisionDx-UM (Class 1A, Class 1B, or Class 2) and DecisionDx-PRAME (negative or positive). This testing was performed by the Castle Biosciences CAP-accredited, CLIA-certified laboratory, as per standard of care. Baseline and follow-up ophthalmic visits were performed as per standard of care at each center but typically included a comprehensive ophthalmic examination, fundus photography, optical coherence tomography, and ultrasonography performed at least every 3-4 months for the first year after treatment, every 4-6 months for the second year, and every 6-12 months thereafter. The primary endpoint was metastasis-free survival (MFS)., , # 15-gene expression profile and PRAME as an integrated prognostic test for uveal melanoma: First report of Collaborative Ocular Oncology Group Study No. 2 (COOG2.1)

[https://doi.org/10.5061/dryad.n8pk0p340](https://doi.org/10.5061/dryad.n8pk0p340)

Tabular data containing 15-GEP/PRAME status, clinical features, and outcomes for patients with uveal melanoma (UM)  enrolled in the Collaborative Ocular Oncology Group Study No. 2 (COOG2).

## Description of the data and file structure

Tabular data (in csv format) for 1,577 anonymised patients enrolled in COOG2.  

Table contains the patients' anonymized ID (COOG2 ID), patient age at study entry, gender, ciliary body involvement (1 = yes, 0 = no), diameter (in mm), thickness (in mm), GEP Class (1 or 2), GEP subtype (A or B for class 1 UM), PRAME staus (1 = positive, 0 = negative), time to last data entry (in months), whether patients developed metastasis (1 = yes, 0= no), months to metastasis or last follow-up (f/u), death status (1 = dead...